ArticlePharmacoepidemiology and drug safety2013

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.

Fei Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.